A Phase 1 clinical trial of NEOK 002
Latest Information Update: 09 Mar 2026
At a glance
- Drugs NEOK 002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 02 Mar 2026 According to NEOK Bio media release, Company plans to initiate a Phase 1 clinical study for NEOK002 in 2Q2026 and share data in 2027.
- 02 Mar 2026 According to NEOK Bio media release, the company announced that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for NEOK002.
- 01 Dec 2025 New trial record